Dr.  Anish Maru

Dr. Anish Maru
Medical Oncologist, Delhi

MBBS, MD (Gen Med), DM (Medical Oncology)

  • 3 Hospitals
  • 17 Years Experience
  • Sr. Consultant in Medical Oncology at Searoc Cancer Center, S. K. Soni Hospital, Jaipur
  • Sr. Consultant in Medical Oncology at Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur
  • Worked as Sr. Resident at ICCU, Heart & General Hospital, Jaipur

Specialities

  • Medical Oncology

  • Oncology

  • Hematology

Expertise

Education

  • Bachelor of Medicine Bachelor of Surgery (MBBS) from SMS Medical College, Jaipur, 1991
  • MD - General Medicine from SMS Medical College, Jaipur, 1995
  • Fellowship in Medical Oncology from Gujarat Cancer & Research Institute (GCRI),Ahmedabad, 1997
  • DM - Medical Oncology from Kidwai Memorial Institute of Oncology, Bangalore, 1999
  • GCP training,Phoenix Clinical Research Services Pvt Ltd. Jaipur

Practice Information

Dharamshila Cancer Hospital & Research Centre, Delhi

Dharamshila Cancer Hospital & Research Centre, Delhi

Dharamshila Marg, Near New Ashok Nagar Metro Station, Vasundhara Enclave, Delhi, Delhi - 110096

Searoc Cancer Center, Jaipur

Searoc Cancer Center, Jaipur

S.K. Soni Hospital Premise, Sikar Road, Sector-5 Vidhyadhay Nagar, Jaipur, Rajasthan - 302013

Action Cancer Hospital, Delhi

Action Cancer Hospital, Delhi

A - 4, Paschim Vihar, Delhi, Delhi - 110063

Patient Experience

Your participation in the survey will help other patients make informed decisions. You will also be helping Dr. Anish Maru and his staff know how they are doing and how they can improve their services.

Achievements & Contributions

  • Research ActivitiesPrincipal Investigator-Phase II clinical trial of IP XXX in refractory solid tumors
  • Research Activities,Principal Investigator-Prospective open label study of drug XXX in postmenopausal women with hormone sensitive advanced breast cancer
  • Research Activities,Principal Investigator-Phase II Randomized control trial on nanoparticle Paclitaxel in Breast Cancer
  • Research Activities,Principal Investigator-A randomised, active control, double- blind, double-dummy, parallel-group, multi-national study to assess the efficacy, tolerability and safety of the IP
  • Research Activities,Principal Investigator-Study entitled `International, Randomized, Open-label, phase 3 Trial Of Paclitaxel/Carboplatin Plus IP XXX Versus Paclitaxel/Carboplatin Alone As First-Line
  • Research Activities,Principal Investigator-A Randomized, Double-Blind, Multicenter Study of IP XXX Compared with Drug YYY in the treatment of Bone Metastases in Subjects with Advanced Breast Cancer
  • Pilot Trial: IP XXX in colorectal cancer.
  • Pilot Trial: IP XXX and Cisplatin in SCLC.
  • Phase IV Trial: IP XXX and Cisplatin in lung cancer.
  • Principal Investigator: Phase II clinical trial of IP XXX in refractory solid tumours.
  • Principal Investigator: Phase I clinical trial of IP XXX in refractory solid tumours.
  • Principal Investigator: Prospective open label study of drug XXX in postmenopausal women with hormone sensitive advanced breast cancer.
  • Principal Investigator: Phase II randomised control trial on nanoparticle Paclitaxel in breast cancer.
  • Authorised: As Physician for GIPAP programme to recommend GLIVEC free for CML and GIST patients.
  • Principal Investigator: Phase IV clinical trial of drug XXX in postmenopausal, receptor positive breast cancer.
  • Principal Investigator: Phase III randomised double-blind placebo controlled trial of IP XXX in Advanced NSCLC.
  • Principal Investigator: Phase III clinical trial to evaluate IP XXX in metastatic renal cell carcinoma.
  • Principal Investigator: Phase II study of IP XXX by inhalation in the treatment of patients with bronchoalveolar carcinoma.
  • Principal Investigator: Phase III comparative trial of IP XXX versus chemo therapeutic agent for third line single agent treatment of patient with relapsed aggressive Non-Hodgkin's lymphoma.
  • Principal Investigator: An open label, phase I, accelerated, dose titration study of IP XXX, A novel IP XXX given orally to adult patients with refractory solid tumours and its safety and efficacy in three entitled refractory solid tumour types namely colon, ovary and small cell lung carcinoma.
  • Principal Investigator: A randomised, active control, double-blind, double-dummy, parallel-group, multi-national study to assess the efficacy, tolerability and safety of the IP XXX transdermal delivery system in chemotherapy – induced nausea and vomiting (CINV) associated with the administration of moderately or highly emetogenic multi-day chemotherapy.
  • Principal Investigator: Study entitled "International, randomised, open-label, phase 3 trial of Paclitaxel/Carboplatin Plus IP XXX versus Paclitaxel/Carboplatin alone as first-line treatment of patients with advanced non-small cell lung cancer".
  • Principal Investigator: A phase 2, randomised, double-masked, placebo-controlled study to evaluate the efficacy of IP XXX in reducing the duration and severity of ulcerative oral mucositis in patients receiving cytotoxic chemotherapy for breast or lung cancer.
  • Publications,`Medullary cervical neurinoma presenting as progressive spastic hemiparesis`. Neurology India, Vol. 38, No. 5, September 1990, page 494.
  • Publications,`Diurnally fluctuating hereditary progressive dystonia with typical feature`. Neurology India 41, 7-39, 1994.
  • Publications,`An unusual association of adult polycystic kidney disease`. Neurology India, 42, 1994.
  • Publications,`Primary reading epilepsy-A case report`. Neurology India. 44, 25-26, 1996.
  • Publications,`Cerebral venous and arterial thrombosis in pregnancy and puerperium - A prospective study`. JAPI 1997, Vol. 45, No. 11, 857-859.
  • Publications,`Asymptomatic Radiological cerebella atrophy with chronic antiepileptic therapy`, JANE I, 2 (I), 69-70, 1997.
  • Publications,`TIA caused by small basal ganglia hematoma`. Accepted for publication in JAPI.
  • Publications,`Benign intracranial hypertension-A review`. Rajasthan Medical Journal (Accepted for publication).
  • Publications,`Recent trends in neurocysticercosis in India`. Rajasthan Medical Journal (Accepted for publication).
  • Publications,`Diagnosis of malaria by detection of plasmodium falciparum HRP-2 antigen with rapid dipstick Antigen capture assay`. Rajasthan Medical Journal (Accepted for publication).
  • Papers Presentation,`Stroke in young in North Western Indian`. 1st International Conference on ODNS, 19-22 November 1994.
  • Papers Presentation,`Chemotherapy in non small cell lung Cancer` 53rd annual Conference of API, January 16-20, 1998.
  • Papers Presentation,`Interferon Alfa in chronic Myeloid Leukemia` Biennial Conference of ISMPO, January 29-31, 1999.
  • Papers Presentation,`Breast Cancer-Review of presentation and management` Poster Presentation at 17th APCC, Bali, Indonesia 8-11 October 2003.
  • Member, Indian Society of Medical and Paediatric Oncology.
  • Member, Indian Society of Haematology and Transfusion Medicine.
  • Member, Indian Co-operative Oncology Network.
  • Member, Indian CML Study Group.
  • Member, Brain Tumour Study Group.
  • Key Opinion Leader for Biocon India Ltd.
  • Key Opinion Leader for Celltrion, South Korea.